Viracta Therapeutics, Inc. (VIRX) - Uzoq muddatli qarzning kapitalga nisbati

Viracta Therapeutics Inc. (VIRX) korporativ emblemasi va logotipi

Viracta Therapeutics (VIRX) Nanistat dorisini antiviral protokollar bilan birlashtirish orqali kompleks aniq o'sma terapiyasi muhitini ishlab chiqmoqda. Ushbu narxlar grafigi aktivning dinamikasini aks ettiradi, bunda uzoq muddatli qarzdorlikning kapitalga nisbati 0.00 darajasida turibdi. Kompaniya asosiy sinov ma'lumotlarini kutayotgan bir paytda limfomalar bilan kurashish uchun epigenetik induksiyaga e'tibor qaratmoqda. Biznes barqarorligi viruslar keltirib chiqaradigan saratonni davolashning muhimligi bilan ta'minlanadi, bu esa daromadlarni inflyatsion zarbalardan mustaqil qiladi.

viracta.com - VIRX Uzoq muddatli qarzning kapitalga nisbati (davr: 04.07.2022 - 16.02.2025)

Viracta Therapeutics kompaniyasining tahliliy kesimlari

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Viracta|VIRX - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor kapitallashuvi Viracta Therapeutics, Inc.|VIRX - Kompaniyaning to‘liq qiymati
- kompaniyaning balans qiymati tafsilotlari:
Bitta aksiya hisobiga xususiy kapital Viracta Therapeutics|VIRX - Balans kapitallashuvi|Kapitallashuvning sof aktivlarga nisbati viracta.com|VIRX - Kompaniyaning umumiy aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Viracta Therapeutics|VIRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati Viracta|VIRX - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Viracta Therapeutics, Inc.|VIRX - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Viracta Therapeutics|Tezkor likvidlik koeffitsiyenti viracta.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
VIRX - Kompaniyaning sof foydasi
Kompaniyaning umumiy tahlili:viracta.com - VIRX
Viracta Therapeutics original mahsuloti

Saratonga qarshi dori vositalarini ishlab chiqish qat'iy likvidlik boshqaruvini talab qiladi, ayniqsa Viracta Therapeutics (VIRX) kompaniyasining klinik sinovlari sekinlashayotgan bir paytda. Ushbu koeffitsient kompaniyaning uzoq muddatli majburiyatlarining kapitalga nisbatan darajasini o'lchaydi. Ushbu ko'rsatkichning pasayishi defolt xavfini minimallashtiradi, ammo kengayishga investitsiyalarning kamayganidan dalolat berishi mumkin. Investorlar tartibga soluvchi o'zgarishlar fonida moliyalashtirish tuzilmasining barqarorligini baholashlari lozim. Uzoq muddatli qarzning kapitalga nisbatini monitoring qilish ushbu o'zgarishlarni tezkorlik bilan kuzatish imkonini beradi.

Muhim raqobatchilar

Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati ARAY (Accuray Inc.)|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|ACTU: Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR - Uzoq muddatli qarzning kapitalga nisbati|tuhurabio.com (HURA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Protara Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|FATE (Fate Therapeutics Corp) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Aadi Bio WHWK|Uzoq muddatli qarzning o'z kapitaliga nisbati TCRX (TScan Therapeutics)|Uzoq muddatli qarzning o'z kapitaliga nisbati CSBR (championsoncology.com)|Uzoq muddatli qarzning kapitalga nisbati XBIT (XBiotech)|Uzoq muddatli qarzdorlikning kapitalga nisbati CEL-SCI Corp. (CVM)|OSTX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti RADX (Radiopharm Theranostics Ltd)|ARTV: Uzoq muddatli qarzning kapitalga nisbati|Adlai Nortye (ANL) - Uzoq muddatli qarzning kapitalga nisbati|VERU (Veru) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Tempest Therapeutics Inc (TPST)|Uzoq muddatli qarzning o'z kapitaliga nisbati XLO (Xilio Therapeutics, Inc.)|Uzoq muddatli kreditlarning kapitalga nisbati RENB|Uzoq muddatli qarzning kapitalga nisbati MURA (Mural Oncology)|Uzoq muddatli qarzning kapitalga nisbati Kairos Pharma Limited KAPA|OKUR: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti GDTC (CytoMed Therapeutics)|CRIS (curis.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|APLM: Uzoq muddatli kreditlarning kapitalga nisbati|THAR (Tharimmune, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|ADVB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati GNPX|CLDI - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Sunshine Biopharma SBFM|Uzoq muddatli qarzning kapitalga koeffitsiyenti XBIO|Salarius Pharmaceuticals - Uzoq muddatli qarzning kapitalga nisbati|PPBT - Uzoq muddatli qarzning kapitalga nisbati|aoncology.com (AONC) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati BGNE (BeiGene Ltd.)|CKPT (Checkpoint Therapeutics, Inc) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Elevation Oncology Inc. ELEV|Uzoq muddatli qarzning o'z kapitaliga nisbati ICAD (iCAD, Inc.)|Uzoq muddatli qarzning kapitalga nisbati ikenaoncology.com (IKNA)|Notable Labs - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli kreditlarning kapitalga nisbati MOR (MorphoSys Inc)|NAYA Bio - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Ascentage AAPGV